![]() I truly believe that when industry and professional organizations work collaboratively, we best position ourselves to advance science and public health." In addition, I am honored and humbled to be receiving the ASGE President's Award. We are also delighted to share new data that informs our understanding of linaclotide’s treatment effect in patients with IBS-C and from its development program in pediatric patients with functional constipation. "We’re particularly excited to showcase new research emphasizing our leadership in the visceral hypersensitivity space, specifically exploring IW-3300’s potential as a treatment option for visceral pain conditions. "DDW is always an invigorating meeting for scientific minds in the GI community, and we’re thrilled to share findings from eight insightful studies in person this year," said Mr. Other studies include preclinical data on the impact of linaclotide on visceral hypersensitivity, data on the impact of linaclotide on pediatric functional constipation (FC) and studies on disease burden of IBS-C and chronic idiopathic constipation (CIC).Īt the meeting, Ironwood’s Chief Executive Officer, Tom McCourt will be honored with the American Society for Gastrointestinal Endoscopy (ASGE) President’s Award, which recognizes individuals who have made exceptional contributions to ASGE and its mission over the course of their careers. The second oral presentation will summarize results of a post-hoc analysis of linaclotide studies focused on further understanding its treatment effect on abdominal symptoms in patients with Irritable Bowel Syndrome with Constipation (IBS-C). Ironwood is focused on advancing the science and understanding of visceral pain and is currently developing IW-3300 for the potential treatment of chronic visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis. One oral presentation will discuss the impact of novel guanylate cyclase-C agonist IW-3300 on comorbid chronic pelvic and somatic pain in a preclinical model of stress-induced visceral hypersensitivity. ![]() (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present eight studies, including two oral presentations, during the Digestive Disease Week ® (DDW) 2022 meeting being held from May 21 through in San Diego, CA. – CEO Tom McCourt to receive American Society for Gastrointestinal Endoscopy (ASGE) President’s Award at meeting –īOSTON, May 09, 2022-( BUSINESS WIRE)- Ironwood Pharmaceuticals, Inc. – Data to be featured in two oral presentations and six posters –
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |